BioArctic AB (publ) 0RV2.IL Stock
BioArctic AB (publ) Price Chart
BioArctic AB (publ) 0RV2.IL Financial and Trading Overview
| BioArctic AB (publ) stock price | 213.5 SEK |
| Previous Close | 344 SEK |
| Open | 0 SEK |
| Bid | 315.6 SEK x 0 |
| Ask | 0 SEK x 0 |
| Day's Range | 0 - 0 SEK |
| 52 Week Range | 0 - 391 SEK |
| Volume | 7.14K SEK |
| Avg. Volume | 17.23K SEK |
| Market Cap | 28.66B SEK |
| Beta (5Y Monthly) | 0.434482 |
| PE Ratio (TTM) | 97.41936 |
| EPS (TTM) | 3.07 SEK |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | May 10, 2019 |
| 1y Target Est | N/A |
0RV2.IL Valuation Measures
| Enterprise Value | 29.22B SEK |
| Trailing P/E | 97.41936 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 46.079437 |
| Price/Book (mrq) | 26.988384 |
| Enterprise Value/Revenue | 46.975 |
| Enterprise Value/EBITDA | 84.41 |
Trading Information
BioArctic AB (publ) Stock Price History
| Beta (5Y Monthly) | 0.434482 |
| 52-Week Change | 367.54% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 391 SEK |
| 52 Week Low | 0 SEK |
| 50-Day Moving Average | 286.72 SEK |
| 200-Day Moving Average | 263.78 SEK |
0RV2.IL Share Statistics
| Avg. Volume (3 month) | 17.23K SEK |
| Avg. Daily Volume (10-Days) | 16.3K SEK |
| Shares Outstanding | 73.83M |
| Float | 37.17M |
| Short Ratio | N/A |
| % Held by Insiders | 47.15% |
| % Held by Institutions | 31.50% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 52.56% |
| Operating Margin (ttm) | 54.50% |
| Gross Margin | 85.60% |
| EBITDA Margin | 55.65% |
Management Effectiveness
| Return on Assets (ttm) | 21.17% |
| Return on Equity (ttm) | 35.72% |
Income Statement
| Revenue (ttm) | 622M SEK |
| Revenue Per Share (ttm) | 7.06 SEK |
| Quarterly Revenue Growth (yoy) | 9439.00% |
| Gross Profit (ttm) | 155.54M SEK |
| EBITDA | 346.15M SEK |
| Net Income Avi to Common (ttm) | 326.93M SEK |
| Diluted EPS (ttm) | 3.41 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.11B SEK |
| Total Cash Per Share (mrq) | 12.54 SEK |
| Total Debt (mrq) | 7.92M SEK |
| Total Debt/Equity (mrq) | 0.73 SEK |
| Current Ratio (mrq) | 16.283 |
| Book Value Per Share (mrq) | 12.309 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 307.04M SEK |
| Levered Free Cash Flow (ttm) | 181.91M SEK |
Profile of BioArctic AB (publ)
| Country | United Kingdom |
| State | N/A |
| City | Stockholm |
| Address | Warfvinges vag 35 |
| ZIP | 112 51 |
| Phone | 46 86 95 69 30 |
| Website | https://www.bioarctic.se |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 69 |
BioArctic AB (publ) develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. It also develops ABBV-0805, for treating Parkinson's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders. Further, it develops BAN1503, AD-BT2802, AD-BT2803, AD1502, AD1503, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814 andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, BAN0805, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Q&A For BioArctic AB (publ) Stock
What is a current 0RV2.IL stock price?
BioArctic AB (publ) 0RV2.IL stock price today per share is 213.5 SEK.
How to purchase BioArctic AB (publ) stock?
You can buy 0RV2.IL shares on the IOB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioArctic AB (publ)?
The stock symbol or ticker of BioArctic AB (publ) is 0RV2.IL.
Which industry does the BioArctic AB (publ) company belong to?
The BioArctic AB (publ) industry is Biotechnology.
How many shares does BioArctic AB (publ) have in circulation?
The max supply of BioArctic AB (publ) shares is 100.03M.
What is BioArctic AB (publ) Price to Earnings Ratio (PE Ratio)?
BioArctic AB (publ) PE Ratio is 69.54550000 now.
What was BioArctic AB (publ) earnings per share over the trailing 12 months (TTM)?
BioArctic AB (publ) EPS is 3.07 SEK over the trailing 12 months.
Which sector does the BioArctic AB (publ) company belong to?
The BioArctic AB (publ) sector is Healthcare.